NCT00992771View on ClinicalTrials.gov

Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Spinocerebellar Ataxia Type 3
Interventions
DRUG

varenicline

up to 1mg BID for 8 weeks

DRUG

placebo

placebo matching varenicline, up to 1mg BID for 8 weeks

Trial Locations (3)

32610

University of Florida, Gainesville

33612

University of South Florida, Tampa

90095

University of California - Los Angeles, Los Angeles

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

National Ataxia Foundation

OTHER

collaborator

Bob Allison Ataxia Research Center (BAARC)

UNKNOWN

collaborator

Pfizer

INDUSTRY

lead

University of South Florida

OTHER

NCT00992771 - Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 | Biotech Hunter | Biotech Hunter